Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

WIN-55,212-2

Cannabinoid receptor agonist
 
BML-CR105-0010 10 mg 72.00 USD
 
BML-CR105-0050 50 mg 295.00 USD
Do you need bulk/larger quantities?
 
Replaces Prod. #: ALX-270-243

High affinity cannabinoid receptor (CB) agonist (Ki=62.3nM and 3.3nM at the human cloned CB1 and CB2 receptors, respectively). Potent analgesic in a rat model of neuropathic pain. Activates p42 and p44 MAP kinase via a receptor-mediated signaling.

Product Specification

Alternative Name:(R)-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone . mesylate
 
Formula:C27H26N2O3 . CH3SO3H
 
MW:522.6
 
CAS:131543-23-2
 
Purity:≥98% (HPLC)
 
Appearance:White to off-white solid.
 
Solubility:Soluble in DMSO; insoluble in water.
 
Shipping:Ambient
 
Long Term Storage:+4°C
 
Use/Stability:Stable for at least 1 year after receipt when stored, as supplied, at 0-4°C. Stock solutions are stable for up to 3 months at -20°C.
 
bml-cr105
Please mouse over
bml-cr105

Product Literature References

Cannabinoid functions in the amygdala contribute to conditioned fear memory in streptozotocin-induced diabetic mice: Interaction with glutamatergic functions: H. Ikeda, et al.; Exp. Neurol. 269, 233 (2015), Application(s): Injection into mice, Abstract;
Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212: J.L. Croxford & S.D. Miller ; J. Clin. Invest. 111, 1231 (2003), Abstract;
Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation: I. Galve-Roperh, et al.; Nat. Med. 6, 313 (2000), Abstract;
An analgesia circuit activated by cannabinoids: I.D. Meng, et al.; Nature 395, 6700 (1998), Abstract;
The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain: U. Herzberg, et al.; Neurosci. Lett. 221, 157 (1997), Abstract;
Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system: X. Pan, et al.; Mol. Pharmacol. 49, 707 (1996), Abstract;
Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1: M. Bouaboula, et al.; Biochem. J. 312, 637 (1995), Abstract;
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors: C.C. Felder, et al.; Mol. Pharmacol. 48, 443 (1995), Abstract;
Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors: J.P. Terranova, et al.; Naunyn-Schmiedeberg's Arch. Pharmacol. 352, 576 (1995), Abstract;
(+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters: A. Richter & W. Loscher; Eur. J. Pharmacol. 264, 371 (1994), Abstract;
Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor: T.E. D'Ambra, et al.; J. Med. Chem. 35, 124 (1992), Abstract;

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
Cannabinoid receptor
MAPK
By biological activity:
Cannabinoid receptor Ligand
MAPK Activator
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Related Literature

Brochures
Essential Research Tools for Neurodegeneration & Neural Signaling
Essential Research Tools for Neurodegeneration & Neural Signaling
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,